Opening Recap
Market Pulse: Stocks edged higher as FDA approval buzz and crypto rotation dominated headlines.
Key Movers: Roche’s Gazyva nod and Novo Nordisk’s oral GLP-1 breakthrough captured attention alongside Luminar’s potential short squeeze.
Macro & Politics: “선거의 수학과 물리” from Tistory.com reminded investors that election math can reshape policy risk overnight.
What’s Next: Keep an eye on FDA decisions and earnings revisions for J.B. Hunt when markets open.
Market Commentary
Everyone’s chasing the biotech approvals while sneaking peeks at crypto, but few are dialing in on gold’s slump and Bitcoin’s stealth rally. Ambcrypto.com flagged capitulation and whale moves that could flip digital gold into a macro safe haven—don’t sleep on that pivot.
Here’s a twist: the election models in “선거의 수학과 물리” and the chatter around Luminar’s squeeze aren’t just separate headlines. Policy risk swings can spark volatility that fuels momentum trades—election math meets meme stocks in a perfect storm for those who play fast.
Your move? Position for choppy sessions. Respect the volatility, size up catalysts—from FDA nods on lupus nephritis to short-squeeze fever—and let the herd’s hesitation work in your favor before they flood in.
📈 Breaking Financial News
Should You Buy the Short Squeeze in Luminar Stock?
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial – Market Pulse – VolatilityVolume & Open InterestHorizontal StrategiesButterfly Strategies – Market PulseResourcesEuropean FuturesEuropean …
Should You Buy the Short Squeeze in Luminar Stock?
Should investors see Luminar’s efforts to improve operational efficiency and LAZR's recent rally as a turning point?
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
Basel, 20 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving stan…
Gold fatigue sets in – Is it finally Bitcoin’s turn to shine?
Capitulation, whale moves, and rising demand could flip Bitcoin from panic to safe haven faster than expected.
First oral GLP-1 cuts cardiovascular risk by 14% – and it's now FDA-approved
The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of cardiovascular events like heart attack and stroke.Continue Re…
🔍 Market Analysis & Insights
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2025. Pluvicto plus sta…
Weekly Stock Market Update: Apple, Taiwan Semiconductor and Novo Nordisk
It was a volatile but ultimately positive week on Wall Street, marked by renewed tensions in the U.S.-China trade war and a strong start to the earnings…
Why Analysts Are Rethinking the Story for J.B. Hunt After Recent Earnings and Market Shifts
J.B. Hunt Transport Services has seen its fair value estimate raised from $157.54 to $163.78, with analysts pointing to ongoing cost initiatives and…
선거의 수학과 물리
The 5 top tables in Dubai, from a buzzy cafe owned by LVMH to a star chef's take on Iraqi cuisine https://t.co/7Ve6wxwXO4— Bloomberg (@business) October 1, 2025 A potential class settlement between Elon Musk‘s X Corp. and laid-off Twitter Inc. employees seeki…
Is the Bitcoin top in? Analyst says ‘not yet’ – Here’s why
BTC keeps disappearing from exchanges.
💰 Investment Opportunities
A Silicon Valley engineer cracked the code to find signs of colon cancer in your blood
Guardant's liquid biopsy only requires a few vials of blood. Can it really prevent cancer?
Brains, Gains & Growing Pains: Inside Mount Sinai’s BCI Crystal Ball
Recap and analysis of Mount Sinai Biodesign's 2025 NY Brain-computer interface symposium, featuring Synchron, Precision, Neuralink, Paradromics, Science Corp #nybci25
S&P 500 Gains and Losses Today: Amex Stock Hits Record High; Oracle and Newmont Plunge
Shares of a major credit card issuer surged on Friday, Oct. 17, 2025, as spending by wealthy cardholders helped drive record revenues, while a retreat in…
Could simple blood tests identify cancer earlier?
Blood tests that detect early cancer are coming to market. Could they lead to earlier diagnosis and treatment?